The alternative NF-κB pathway from biochemistry to biology: Pitfalls and promises for future drug development

Biochemical Pharmacology

Volumn 72, Issue 9 SPEC. ISS., 2006, Pages 1161-1179

  Dejardin, Emmanuel ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Alternative pathway; IKK; Inflammation; NF B; NIK; p100 p52

Indexed keywords

BELIMUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE BETA RECEPTOR; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RECEPTOR;

ARTHRITIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE DEVELOPMENT; CARCINOGENESIS; CELL MATURATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG RESEARCH; ENTEROPATHY; ENZYME ACTIVATION; GENETIC ANALYSIS; HUMAN; IMMUNOBIOLOGY; IMMUNOCHEMISTRY; IMMUNOPHARMACOLOGY; INFLAMMATORY DISEASE; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TRANSPORT; RECEPTOR INTRINSIC ACTIVITY; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANIMAL; CELL TRANSFORMATION; GROWTH, DEVELOPMENT AND AGING; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; THYMUS;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; THYMUS GLAND;

EID: 33749265867     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.08.007     Document Type: Article

References (148)

1. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl. (2002) S81-S96
2. Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev 18 (2004) 2195-2224
3. Siebenlist U., Franzoso G., and Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10 (1994) 405-455
4. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
5. Ducut Sigala J.L., Bottero V., Young D.B., Shevchenko A., Mercurio F., and Verma I.M. Activation of transcription factor NF-kappaB requires ELKS, an IkappaB kinase regulatory subunit. Science 304 (2004) 1963-1967
6. Chen G., Cao P., and Goeddel D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 9 (2002) 401-410
7. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
8. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293 (2001) 1495-1499
9. Xiao G., Harhaj E.W., and Sun S.C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 7 (2001) 401-409
10. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17 (2002) 525-535
11. Claudio E., Brown K., Park S., Wang H., and Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3 (2002) 958-965
12. Luftig M., Yasui T., Soni V., Kang M.S., Jacobson N., Cahir-McFarland E., et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci USA 101 (2004) 141-146
13. Atkinson P.G., Coope H.J., Rowe M., and Ley S.C. Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. J Biol Chem 278 (2003) 51134-51142
14. Eliopoulos A.G., Caamano J.H., Flavell J., Reynolds G.M., Murray P.G., Poyet J.L., et al. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 22 (2003) 7557-7569
15. Qu Z., Qing G., Rabson A., and Xiao G. Tax deregulation of NF-kappaB2 p100 processing involves both beta-TrCP-dependent and -independent mechanisms. J Biol Chem 279 (2004) 44563-44572
16. Saito N., Courtois G., Chiba A., Yamamoto N., Nitta T., Hironaka N., et al. Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. J Biol Chem 278 (2003) 46565-46575
17. Xiao G., Fong A., and Sun S.C. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 279 (2004) 30099-30105
18. Betts J.C., and Nabel G.J. Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences. Mol Cell Biol 16 (1996) 6363-6371
19. Heusch M., Lin L., Geleziunas R., and Greene W.C. The generation of nfkb2 p52: mechanism and efficiency. Oncogene 18 (1999) 6201-6208
20. Qing G., and Xiao G. Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J Biol Chem 280 (2005) 9765-9768
21. Dejardin E., Bonizzi G., Bellahcène A., Castronovo V., Merville M.-P., and Bours V. Highly-expressed p100/p52 (NFKB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11 (1995) 1835-1841
22. Naumann M., Nieters A., Hatada E.N., and Scheidereit C. NF-kappa B precursor p100 inhibits nuclear translocation and DNA binding of NF-kappa B/rel-factors. Oncogene 8 (1993) 2275-2281
23. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72 (1993) 729-739
24. Dejardin E., Deregowski V., Greimers R., Cai Z., Chouaib S., Merville M.P., et al. Regulation of major histocompatibility complex class I expression by NF-kappaB-related proteins in breast cancer cells. Oncogene 16 (1998) 3299-3307
25. Derudder E., Dejardin E., Pritchard L.L., Green D.R., Korner M., and Baud V. RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem 278 (2003) 23278-23284
26. Kanno T., Franzoso G., and Siebenlist U. Human T-cell leukemia virus type I Tax-protein-mediated activation of NF-kappa B from p100 (NF-kappa B2)-inhibited cytoplasmic reservoirs. Proc Natl Acad Sci USA 91 (1994) 12634-12638
27. Coope H.J., Atkinson P.G., Huhse B., Belich M., Janzen J., Holman M.J., et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 21 (2002) 5375-5385
28. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17 (2002) 515-524
29. Muller J.R., and Siebenlist U. Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J Biol Chem 278 (2003) 12006-12012
30. Liao G., Zhang M., Harhaj E.W., and Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279 (2004) 26243-26250
31. Amir R.E., Haecker H., Karin M., and Ciechanover A. Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase. Oncogene 23 (2004) 2540-2547
32. Fong A., and Sun S.C. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J Biol Chem 277 (2002) 22111-22114
33. Liang C., Zhang M., and Sun S.C. beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870. Cell Signal (2005)
34. Fong A., Zhang M., Neely J., and Sun S.C. S9, a 19 S proteasome subunit interacting with ubiquitinated NF-kappaB2/p100. J Biol Chem 277 (2002) 40697-40702
35. Lanoix J., Lacoste J., Pepin N., Rice N., and Hiscott J. Overproduction of NFKB2 (lyt-10) and c-Rel: a mechanism for HTLV-I Tax-mediated trans-activation via the NF-kappa B signalling pathway. Oncogene 9 (1994) 841-852
36. Paine E., Scheinman R.I., Baldwin Jr. A.S., and Raab-Traub N. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol 69 (1995) 4572-4576
37. Xiao G., Cvijic M.E., Fong A., Harhaj E.W., Uhlik M.T., Waterfield M., et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J 20 (2001) 6805-6815
38. Matta H., and Chaudhary P.M. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA 101 (2004) 9399-9404
39. Ohmae T., Hirata Y., Maeda S., Shibata W., Yanai A., Ogura K., et al. Helicobacter pylori activates NF-kappaB via the alternative pathway in B lymphocytes. J Immunol 175 (2005) 7162-7169
40. Mordmuller B., Krappmann D., Esen M., Wegener E., and Scheidereit C. Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism. EMBO Rep 4 (2003) 82-87
41. Liao G., and Sun S.C. Regulation of NF-kappaB2/p100 processing by its nuclear shuttling. Oncogene 22 (2003) 4868-4874
42. Orian A., Schwartz A.L., Israel A., Whiteside S., Kahana C., and Ciechanover A. Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain. Mol Cell Biol 19 (1999) 3664-3673
43. Stoven S., Silverman N., Junell A., Hedengren-Olcott M., Erturk D., Engstrom Y., et al. Caspase-mediated processing of the Drosophila NF-kappaB factor Relish. Proc Natl Acad Sci USA 100 (2003) 5991-5996
44. Liptay S., Schmid R.M., Nabel E.G., and Nabel G.J. Transcriptional regulation of NF-κB2: evidence for κB-mediated positive and negative autoregulation. Mol Cell Biol 14 (1994) 7695-7703
45. Lombardi L., Ciana P., Cappellini C., Trecca D., Guerrini L., Migliazza A., et al. Structural and functional characterization of the promoter regions of the NFKB2 gene. Nucleic Acids Res 23 (1995) 2328-2336
46. Hauer J., Puschner S., Ramakrishnan P., Simon U., Bongers M., Federle C., et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 102 (2005) 2874-2879
47. Saitoh T., Nakayama M., Nakano H., Yagita H., Yamamoto N., and Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 278 (2003) 36005-36012
48. Grech A.P., Amesbury M., Chan T., Gardam S., Basten A., and Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 21 (2004) 629-642
49. Oganesyan G., Saha S.K., Guo B., He J.Q., Shahangian A., Zarnegar B., et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439 (2006) 208-211
50. Xu Y., Cheng G., and Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 5 (1996) 407-415
51. Ishikawa H., Carrasco D., Claudio E., Ryseck R.-P., and Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med 186 (1997) 999-1014
52. Leonardi A., Chariot A., Claudio E., Cunningham K., and Siebenlist U. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc Natl Acad Sci USA 97 (2000) 10494-10499
53. Li X., Commane M., Nie H., Hua X., Chatterjee-Kishore M., Wald D., et al. Act1, an NF-kappa B-activating protein. Proc Natl Acad Sci USA 97 (2000) 10489-10493
54. Qian Y., Qin J., Cui G., Naramura M., Snow E.C., Ware C.F., et al. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity 21 (2004) 575-587
55. Hu W.H., Mo X.M., Walters W.M., Brambilla R., and Bethea J.R. TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation. J Biol Chem 279 (2004) 35975-35983
56. Dobrzanski P., Ryseck R.P., and Bravo R. Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 10 (1995) 1003-1007
57. Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville M.P., et al. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 18 (1999) 2567-2577
58. Maier H.J., Marienfeld R., Wirth T., and Baumann B. Critical role of RelB serine 368 for dimerization and p100 stabilization. J Biol Chem 278 (2003) 39242-39250
59. Kyewski B., and Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 4 (2004) 688-698
60. Boehm T., Scheu S., Pfeffer K., and Bleul C.C. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTbetaR. J Exp Med 198 (2003) 757-769
61. Chin R.K., Lo J.C., Kim O., Blink S.E., Christiansen P.A., Peterson P., et al. Lymphotoxin pathway directs thymic Aire expression. Nat Immunol 4 (2003) 1121-1127
62. Kajiura F., Sun S., Nomura T., Izumi K., Ueno T., Bando Y., et al. NF-kappa B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. J Immunol 172 (2004) 2067-2075
63. Kinoshita D., Hirota F., Kaisho T., Kasai M., Izumi K., Bando Y., et al. Essential role of IkappaB kinase alpha in thymic organogenesis required for the establishment of self-tolerance. J Immunol 176 (2006) 3995-4002
64. Burkly L., Hession C., Ogata L., Reilly C., Marconi L.A., Olson D., et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373 (1995) 531-536
65. Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P., et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80 (1995) 331-340
66. Zuklys S., Balciunaite G., Agarwal A., Fasler-Kan E., Palmer E., and Hollander G.A. Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Immunol 165 (2000) 1976-1983
67. Cupedo T., Kraal G., and Mebius R.E. The role of CD45 + CD4 + CD3-cells in lymphoid organ development. Immunol Rev 189 (2002) 41-50
68. Mebius R.E. Organogenesis of lymphoid tissues. Nat Rev Immunol 3 (2003) 292-303
69. Weih F., and Caamano J. Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev 195 (2003) 91-105
70. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23 (2005) 787-819
71. Banks T.A., Rouse B.T., Kerley M.K., Blair P.J., Godfrey V.L., Kuklin N.A., et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 155 (1995) 1685-1693
72. De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264 (1994) 703-707
73. Futterer A., Mink K., Luz A., Kosco-Vilbois M.H., and Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9 (1998) 59-70
74. Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., and Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 195 (2002) 1613-1624
75. Shinkura R., Kitada K., Matsuda F., Tashiro K., Ikuta K., Suzuki M., et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 22 (1999) 74-77
76. Yin L., Wu L., Wesche H., Arthur C.D., White J.M., Goeddel D.V., et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 291 (2001) 2162-2165
77. Yoshida H., Naito A., Inoue J., Satoh M., Santee-Cooper S.M., Ware C.F., et al. Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph nodes and Peyer's patches. Immunity 17 (2002) 823-833
78. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 (1999) 2412-2424
79. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
80. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97 (2000) 1566-1571
81. Kim D., Mebius R.E., MacMicking J.D., Jung S., Cupedo T., Castellanos Y., et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 192 (2000) 1467-1478
82. Alcamo E., Hacohen N., Schulte L.C., Rennert P.D., Hynes R.O., and Baltimore D. Requirement for the NF-kappaB family member RelA in the development of secondary lymphoid organs. J Exp Med 195 (2002) 233-244
83. Yilmaz Z.B., Weih D.S., Sivakumar V., and Weih F. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 22 (2003) 121-130
84. Drayton D.L., Bonizzi G., Ying X., Liao S., Karin M., and Ruddle N.H. I kappa B kinase complex alpha kinase activity controls chemokine and high endothelial venule gene expression in lymph nodes and nasal-associated lymphoid tissue. J Immunol 173 (2004) 6161-6168
85. Sha W.C., Liou H.-C., Tuomanen E.I., and Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80 (1995) 321-330
86. Carragher D., Johal R., Button A., White A., Eliopoulos A., Jenkinson E., et al. A stroma-derived defect in NF-kappaB2-/- mice causes impaired lymph node development and lymphocyte recruitment. J Immunol 173 (2004) 2271-2279
87. Lo J.C., Basak S., James E.S., Quiambo R.S., Kinsella M.C., Alegre M.L., et al. Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. Blood 107 (2006) 1048-1055
88. Cupedo T., and Mebius R.E. Cellular interactions in lymph node development. J Immunol 174 (2005) 21-25
89. Muller G., and Lipp M. Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development. Curr Opin Immunol 15 (2003) 217-224
90. Saccani S., Pantano S., and Natoli G. Modulation of NF-kappaB activity by exchange of dimers. Mol Cell 11 (2003) 1563-1574
91. Novack D.V., Yin L., Hagen-Stapleton A., Schreiber R.D., Goeddel D.V., Ross F.P., et al. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198 (2003) 771-781
92. Ishimaru N., Kishimoto H., Hayashi Y., and Sprent J. Regulation of naive T cell function by the NF-kappaB2 pathway. Nat Immunol (2006)
93. Fukuyama S., Hiroi T., Yokota Y., Rennert P.D., Yanagita M., Kinoshita N., et al. Initiation of NALT organogenesis is independent of the IL-7R, LTbetaR, and NIK signaling pathways but requires the Id2 gene and CD3(-)CD4(+)CD45(+) cells. Immunity 17 (2002) 31-40
94. Siebenlist U., Brown K., and Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 5 (2005) 435-445
95. Schwarz E.M., Krimpenfort P., Berns A., and Verma I.M. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev 11 (1997) 187-197
96. Franzoso G., Carlson L., Scharton-Kersten T., Shores E.W., Epstein S., Grinberg A., et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 6 (1997) 479-490
97. Poljak L., Carlson L., Cunningham K., Kosco-Vilbois M.H., and Siebenlist U. Distinct activities of p52/NF-kappa B required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J Immunol 163 (1999) 6581-6588
98. Bonizzi G., Bebien M., Otero D.C., Johnson-Vroom K.E., Cao Y., Vu D., et al. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB: p52 dimers. EMBO J 23 (2004) 4202-4210
99. Matsumoto M. Role of TNF ligand and receptor family in the lymphoid organogenesis defined by gene targeting. J Med Invest 46 (1999) 141-150
100. Rolink A.G., Schaniel C., Andersson J., and Melchers F. Selection events operating at various stages in B cell development. Curr Opin Immunol 13 (2001) 202-207
101. Gerondakis S., Grossmann M., Nakamura Y., Pohl T., and Grumont R. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene 18 (1999) 6888-6895
102. Horwitz B.H., Scott M.L., Cherry S.R., Bronson R.T., and Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-kappaB-deficient fetal liver cells. Immunity 6 (1997) 765-772
103. Senftleben U., Li Z.W., Baud V., and Karin M. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 14 (2001) 217-230
104. Kim S., La Motte-Mohs R.N., Rudolph D., Zuniga-Pflucker J.C., and Mak T.W. The role of nuclear factor-kappaB essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci USA 100 (2003) 1203-1208
105. Pasparakis M., Schmidt-Supprian M., and Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med 196 (2002) 743-752
106. Karrer U., Althage A., Odermatt B., Hengartner H., and Zinkernagel R.M. Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect of secondary lymphoid organs and functional B cell defect. Eur J Immunol 30 (2000) 2799-2807
107. Koike R., Nishimura T., Yasumizu R., Tanaka H., Hataba Y., Hataba Y., et al. The splenic marginal zone is absent in alymphoplastic aly mutant mice. Eur J Immunol 26 (1996) 669-675
108. Yamada T., Mitani T., Yorita K., Uchida D., Matsushima A., Iwamasa K., et al. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase. J Immunol 165 (2000) 804-812
109. Kaisho T., Takeda K., Tsujimura T., Kawai T., Nomura F., Terada N., et al. IkappaB kinase alpha is essential for mature B cell development and function. J Exp Med 193 (2001) 417-426
110. Hsu B.L., Harless S.M., Lindsley R.C., Hilbert D.M., and Cancro M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168 (2002) 5993-5996
111. Grossmann M., O'Reilly L.A., Gugasyan R., Strasser A., Adams J.M., and Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 19 (2000) 6351-6360
112. Sasaki Y., Derudder E., Hobeika E., Pelanda R., Reth M., Rajewsky K., et al. Canonical NF-kappaB activity, dispensable for B Cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 24 (2006) 729-739
113. Zarnegar B., He J.Q., Oganesyan G., Hoffmann A., Baltimore D., and Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci USA 101 (2004) 8108-8113
114. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
115. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15 (2004) 457-475
116. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11 (1997) 3482-3496
117. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3 (1997) 1285-1289
118. Caamano J.H., Rizzo C.A., Durham S.K., Barton D.S., Raventos-Suarez C., Snapper C.M., et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 187 (1998) 185-196
119. Franzoso G., Carlson L., Poljak L., Shores E.W., Epstein S., Leonardi A., et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 187 (1998) 147-159
120. Köntgen F., Grumont R.J., Strasser A., Metcalf D., Li R., Tarlinton D., et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 9 (1995) 1965-1977
121. Weih F., Durham S.K., Barton D.S., Sha W.C., Baltimore D., and Bravo R. Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. J Immunol 157 (1996) 3974-3979
122. Ruocco M.G., Maeda S., Park J.M., Lawrence T., Hsu L.C., Cao Y., et al. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201 (2005) 1677-1687
123. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., et al. X-linked anhydrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 27 (2001) 277-285
124. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V., et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107 (2001) 763-775
125. Chaisson M.L., Branstetter D.G., Derry J.M., Armstrong A.P., Tometsko M.E., Takeda K., et al. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279 (2004) 54841-54848
126. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6 (2006) 205-217
127. Drayton D.L., Liao S., Mounzer R.H., and Ruddle N.H. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 7 (2006) 344-353
128. Gommerman J.L., and Browning J.L. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3 (2003) 642-655
129. Chen C.M., You L.R., Hwang L.H., and Lee Y.H. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 71 (1997) 9417-9426
130. Matsumoto M., Hsieh T.Y., Zhu N., Van Arsdale T., Hwang S.B., Jeng K.S., et al. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 71 (1997) 1301-1309
131. Ng L.G., Mackay C.R., and Mackay F. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 42 (2005) 763-772
132. Edwards J.C., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403
133. Aya K., Alhawagri M., Hagen-Stapleton A., Kitaura H., Kanagawa O., and Veis Novack D. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 115 (2005) 1848-1854
134. Chang C.C., Zhang J., Lombardi L., Neri A., and Dalla-Favera R. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol 15 (1995) 5180-5187
135. Fracchiolla N.S., Lombardi L., Salina M., Migliazza A., Baldini L., Berti E., et al. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene 8 (1993) 2839-2845
136. Migliazza A., Lombardi L., Rocchi M., Trecca D., Chang C.C., Antonacci R., et al. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood 84 (1994) 3850-3860
137. Neri A., Chang C.C., Lombardi L., Salina M., Corradini P., Maiolo A.T., et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 67 (1991) 1075-1087
138. Neri A., Fracchiolla N.S., Migliazza A., Trecca D., and Lombardi L. The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma 23 (1996) 43-48
139. Zhang J., Chang C.C., Lombardi L., and Dalla-Favera R. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 9 (1994) 1931-1937
140. Westerheide S.D., Mayo M.W., Anest V., Hanson J.L., and Baldwin Jr. A.S. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol 21 (2001) 8428-8436
141. Cogswell P.C., Guttridge D.C., Funkhouser W.K., and Baldwin Jr. A.S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19 (2000) 1123-1131
142. Rocha S., Martin A.M., Meek D.W., and Perkins N.D. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol 23 (2003) 4713-4727
143. Scian M.J., Stagliano K.E., Anderson M.A., Hassan S., Bowman M., Miles M.F., et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25 (2005) 10097-10110
144. He B., Raab-Traub N., Casali P., and Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 171 (2003) 5215-5224
145. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3 (2003) 801-812
146. Ramakrishnan P., Wang W., and Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 21 (2004) 477-489
147. Nishikori M., Ohno H., Haga H., and Uchiyama T. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci 96 (2005) 487-497
148. Qing G., Qu Z., and Xiao G. Regulation of NF-kappa B2 p100 processing by its cis-acting domain. J Biol Chem 280 (2005) 18-27